Ragosa Mark: insider trades.
Ragosa Mark reported 5 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 0 sales, across 1 company.
- Transactions
- 5
- Purchases (P)
- 0
- Sales (S)
- 0
- Companies
- 1
- Name as filed
- Ragosa Mark
Companies
| Company | Relationship | Transactions |
|---|---|---|
| Kiniksa Pharmaceuticals International, plc (KNSA) | Officer · CHIEF FINANCIAL OFFICER | 5 |
Transactions
| Date | Company | Code | Shares | Price | Owned after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-01 | Kiniksa Pharmaceuticals International, plc | M | 2,694 | — | 18,848 | Form 4 |
| 2026-09-01 | Kiniksa Pharmaceuticals International, plc | M | 1,750 | — | 20,598 | Form 4 |
| 2026-09-01 | Kiniksa Pharmaceuticals International, plc | F | 4,404 | $79.28 | 20,854 | Form 4 |
| 2026-09-01 | Kiniksa Pharmaceuticals International, plc | M | 3,069 | — | 25,258 | Form 4 |
| 2026-09-01 | Kiniksa Pharmaceuticals International, plc | M | 1,591 | — | 22,189 | Form 4 |
Questions
What stock did Ragosa Mark buy or sell?
Ragosa Mark reported 5 non-derivative transactions on 1 SEC ownership filings in Q3 2026: 0 open-market purchases and 0 sales, across 1 company.
Is Ragosa Mark the same person as other filers with this name?
This page covers SEC CIK 1835458 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.
Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.
Plain-text version for agents and LLMs: /insiders/ragosa-mark-1835458.md
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.